Illumina Service Contract

The National Institutes of Health, through its National Human Genome Research Institute and the Intramural Sequencing Center, is soliciting services under a Firm-Fixed-Price contract to ensure the continued operation and maintenance of Illumina sequencing instruments critical to its high-throughput DNA sequencing pipeline. The contract, identified by solicitation number 75N98026Q00349, is aimed at maintaining the operational readiness of these instruments to support genome research and its application to human health, with performance required at NIH facilities in Bethesda, Maryland. The period of performance runs from June 5, 2026, to June 4, 2027, with optional extensions of up to six months allowed under the contract. Deliveries are to be made F.O.B. destination within the consignee’s premises, and invoicing must follow NIH-specific instructions, including submission of the Unique Entity Identifier and Taxpayer Identification Number. The contract includes several key Federal Acquisition Regulation clauses and special requirements, such as compliance with the HHS salary cap limiting personnel compensation to Federal Executive Schedule Level II, mandatory use of an Earned Value Management System aligned with ANSI/EIA-748 standards, and requirements for an Integrated Baseline Review within 90 days of award. Contractors must also comply with financial conflict of interest reporting under 45 CFR Part 94 and adhere to government property management clauses, including FAR 52.245-1 with Alternate I. The contract allows for increased quantity options on separately priced line items and includes economic price adjustment provisions for labor and materials. Payment will be processed by the Office of Logistics and Office of Administration in Rockville, Maryland, with invoices subject to prompt payment rules. While the solicitation requires technical and cost proposals with SAM.gov registration, no specific page limits or electronic submission portal is stated, and the full packaging and marking details from Section D, as well as detailed evaluation factors, remain incomplete or undisclosed in the available documentation.